Key clinical point: Prophylactic treatment with monthly or quarterly fremanezumab demonstrated favorable efficacy and tolerability in a real-world cohort of patients with episodic migraine (EM) or chronic migraine (CM).
Major finding: After initiating fremanezumab, the monthly migraine days reduced by 6.1, 7.7, and 8.5 days at 1, 3, and 6 months, respectively, with similar reductions observed when categorized by EM or CM (all P < .001). At 6 months, ≥50%, ≥75%, and 100% response rates were achieved by 67.6%, 22.5%, and 5.4% of patients in the overall cohort, respectively, with 48.0% of patients with CM experiencing remission to EM after 1-month fremanezumab treatment. Overall, 9.5% of the patients experienced adverse reactions, which were mostly mild.
Study details: Findings are from a retrospective study that included 127 patients with migraine (EM n = 54; CM n = 73) who received monthly or quarterly fremanezumab doses over 6 months.
Disclosures: This study received no specific funding from any source. Four authors declared receiving lecture fees from various sources.
Source: Suzuki S et al. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285 (Jul 6). Doi: 10.3389/fneur.2023.1220285